In 2023, the company commenced a Phase I/II trial to assess the immune response and safety of pandemic influenza vaccine. Credit: pcruciatti/Shutterstock.

Moderna is set to receive $590m in funding from the US Department of Health and Human Services (HHS) to expedite the development of mRNA-based pandemic influenza vaccines.

The initiative is part of a broader effort to enhance the US’s preparedness for future infectious diseases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The substantial investment was funded by the part of HHS Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV) Consortium.

The funds aim to expedite the late-stage development and licensing of the company’s pre-pandemic vaccines.

The agreement will enable the expansion of trials for up to five additional pandemic influenza subtypes.

Moderna is currently focusing on the development of an H5N1 mRNA influenza vaccine, which aligns with the strains present in cattle and birds.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2023, the company commenced a Phase I/II trial to assess the immune response and safety of its pandemic influenza vaccine, mRNA-1018, in adults.

The trial targets H5 and H7 avian influenza viruses. Following encouraging preliminary outcomes, the company is preparing for Phase III. It is also set to design and conduct a Phase III clinical study for an H7N9 mRNA pandemic influenza vaccine, which could become the first licensed vaccine for H7N9 if successful.

BARDA’s collaboration with the company began in 2023 to create mRNA vaccines for potential public health emergencies due to influenza viruses, such as avian influenza A(H5N1).

The company plans to design up to four new pandemic influenza vaccines and test them in Phase I trials.

In November 2024, Moderna gained approval from Health Canada for its mRNA vaccine, mRESVIA, aimed at preventing lower respiratory tract disease caused by the respiratory syncytial virus in those aged 60 and above.

mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.